Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.

Expert opinion on therapeutic targets - 1 Jan 2000

Rechberger Julian S, Bouchal Samantha M, Power Erica A, Nonnenbroich Leo F, Nesvick Cody L, Daniels David J

Abstract excerpt

INTRODUCTION: H3 K27-altered diffuse midline glioma (DMG) is the most common malignant brainstem tumor in the pediatric population. Despite enormous preclinical and clinical efforts, the prognosis remains dismal, with fewer than 10% of patients surviving for two years after diagnosis. Fractionated radiation remains the only standard treatment options for DMG. Developing novel treatments and therapeutic delivery...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Histones

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37897190
DOI: 10.1080/14728222.2023.2277232
PMCID: PMC11079776

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.PMID 37897190Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity Read ↗

A road map for the treatment of pediatric diffuse midline glioma.Semantic proximity Read ↗

H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.Semantic proximity Read ↗

Diffuse midline glioma treated with epigenetic agent-based immunotherapySemantic proximity Read ↗

Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeuticsSemantic proximity Read ↗

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategiesSemantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments.Semantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.